Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Uniqure Ord Shs
(NQ:
QURE
)
6.030
+0.700 (+13.13%)
Streaming Delayed Price
Updated: 2:12 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Uniqure Ord Shs
< Previous
1
2
Next >
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
September 23, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
August 15, 2024
From
uniQure Inc.
Via
GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
August 01, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
July 23, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
July 09, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
July 01, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 29, 2023
Patient enrollment expected to begin in first half of 2024
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 07, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 05, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 05, 2023
Clinical trial initiation expected in the fourth quarter of 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
June 26, 2023
~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~
From
uniQure Inc.
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
June 22, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
June 21, 2023
From
The Schall Law Firm
Via
Business Wire
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023
From
uniQure Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.